Organon & Co. (OGN) To Go Ex-Dividend on May 12th

Organon & Co. (NYSE:OGN) announced a quarterly dividend on Friday, May 2nd, Wall Street Journal reports. Stockholders of record on Monday, May 12th will be paid a dividend of 0.02 per share on Thursday, June 12th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date of this dividend is Monday, May 12th.

Organon & Co. has raised its dividend payment by an average of 26.0% per year over the last three years. Organon & Co. has a payout ratio of 28.1% meaning its dividend is sufficiently covered by earnings. Analysts expect Organon & Co. to earn $3.74 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 29.9%.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $9.60 on Friday. The firm has a market capitalization of $2.50 billion, a P/E ratio of 2.88, a PEG ratio of 0.90 and a beta of 0.73. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The company has a 50 day moving average price of $13.46 and a 200 day moving average price of $14.94. Organon & Co. has a 52 week low of $9.18 and a 52 week high of $23.10.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, May 1st. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.13. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The business had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same quarter last year, the company posted $1.22 earnings per share. The business’s quarterly revenue was down 6.7% on a year-over-year basis. Sell-side analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Wall Street Analyst Weigh In

OGN has been the subject of a number of research reports. Morgan Stanley lowered their price target on Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th. Barclays dropped their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Evercore ISI downgraded shares of Organon & Co. from an “outperform” rating to an “inline” rating in a report on Friday. Finally, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Organon & Co. currently has an average rating of “Hold” and an average price target of $19.67.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.